Parkinson's Disease/Movement Disorders News

A clinical-stage biopharma firm announced it has been granted a U.S. patent expanding coverage of a novel oral therapy to treat various conditions associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein.

The FDA has approved a battery-powered rechargeable deep brain stimulation system for patients with Parkinson’s disease and other disorders such as essential tremor, epilepsy and dystonia, according to the manufacturer.

According to results of a recent survey, more than 80% of U.S.-based neurologists agreed that a major unmet need in confronting Huntington’s disease is halting neurodegeneration prior to the onset of symptoms.

Nipocalimab showed evidence of dose-dependent, statistically significant symptom reductions in patients with generalized myasthenia gravis, while remaining generally safe and well-tolerated, in a phase 2 trial.

Healio Neurology looks back at the most-viewed stories throughout the year. Highlights include the FDA’s approval of Leqembi to treat Alzheimer’s disease and the regulatory body’s clearing of a blood test for concussions.

Meaningful progress is being made in the development of gene therapies for rare neurological diseases caused by single gene mutations.

The FDA has cleared for marketing “the world’s first” cloud-based software for clinical analysis of neuromelanin-sensitive MRI scans, according to a press release from the manufacturer.

A gene therapy company has announced updated interim data from ongoing United States and European phase 1/2 clinical trials of AMT-130 to treat Huntington’s disease.

A clinical-stage biopharmaceutical company has announced positive findings from the exploratory SHAPE phase 2 clinical trial to evaluate fosgonimeton in those with Parkinson’s disease dementia and dementia with Lewy bodies.

A company specializing in therapeutics for rare and neurodegenerative diseases has announced a partnership with a provider of innovative solutions in early-stage drug discovery to develop a BRD9 inhibitor to treat Huntington’s disease.